Product Information
CREXONT ER 87.5 MG-350 MG CAP is a brand product labeled by Amneal Pharmaceuticals LLC, priced at $4.5825 per EA under NDC 64896097016. Its NADAC has been published 76 times since Apr 23, 2025.
FDA first approved this application on Aug 7, 2024.
The High Outlier badge above means this manufacturer's average price in the carbidopa and levodopa market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
87.5; 350 mg/1; mg/1
Manufacturer
Amneal Pharmaceuticals LLCNDC
64896097016
Classification
Brand
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
7/1/2026
Active Ingredients
CARBIDOPA; LEVODOPAApproval Type
New Drug (NDA)
FDA Application
NDA217186FDA Approved
8/7/2024
On Market Since
8/9/2024
Pharmacological Classes
Price Statistics
The NADAC for CREXONT ER 87.5 MG-350 MG CAP has been published 76 times since Apr 23, 2025, and over the history we have for it it has risen 11.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $4.5825 per EA |
|---|---|
| All-time high | $4.5825 (Sep 30, 2026) |
| All-time low | $4.1172 (Apr 23, 2025) |
| 52-week high | $4.5825 |
| 52-week low | $4.3423 |
| Median price | $4.3573 |
| Average price | $4.3605 |
| Largest weekly change | +5.0% (Jul 8, 2026) |
| Weeks tracked | 76 |
| Tracking since | Apr 23, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the carbidopa and levodopa market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Amneal Pharmaceuticals LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
carbidopa and levodopa market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aromatic Amino Acid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CREXONT ER 87.5 MG-350 MG CAP?
The current National Average Drug Acquisition Cost (NADAC) for CREXONT ER 87.5 MG-350 MG CAP, manufactured by Amneal Pharmaceuticals LLC, is $4.5825 per EA (NDC 64896097016), effective Sep 30, 2026.
How has the price of CREXONT ER 87.5 MG-350 MG CAP changed over time?
Over the history we have for it, the NADAC for CREXONT ER 87.5 MG-350 MG CAP has risen 11.3%. It has been tracked across 76 weekly CMS publications since Apr 23, 2025.
What are the highest and lowest recorded NADAC prices for CREXONT ER 87.5 MG-350 MG CAP?
Since Apr 23, 2025, the NADAC for CREXONT ER 87.5 MG-350 MG CAP has ranged from a low of $4.1172 (Apr 23, 2025) to a high of $4.5825 (Sep 30, 2026), with a median of $4.3573 per EA.
Are there cheaper alternatives to CREXONT ER 87.5 MG-350 MG CAP?
No other NADAC-published product currently shares the active ingredient and strength of CREXONT ER 87.5 MG-350 MG CAP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures CREXONT ER 87.5 MG-350 MG CAP?
CREXONT ER 87.5 MG-350 MG CAP (NDC 64896097016) is labeled by Amneal Pharmaceuticals LLC, and CMS classifies it as a brand product.